CRISPR THERAPEUTICS AG

CRISPR Therapeutics CFO’s 25,000 RSU purchase signals long‑term confidence amid breakthrough Phase II data for CTX‑01 and early safety success for CTX‑02, hinting at future regulatory approvals and shareholder value growth.

George Simeon’s latest insider trade shows confidence in CRISPR Therapeutics’ gene‑editing future—buying shares at €14 while monetizing options near €50, hinting at potential upside.

Insider James KASINGER’s strategic buy‑sell moves at CRISPR Therapeutics signal long‑term confidence in the gene‑editing firm’s pipeline, offering investors a nuanced view of potential upside amid market dips.

CRISPR Therapeutics insider buy shows confidence: James Kasinger’s €141k purchase signals strategic optimism amid market dip and enzyme breakthrough.